DBT Reduces Suicide Attempts More Than SSRIs in Borderline Personality Disorder — First Head-to-Head RCT
- RCT of 84 individuals with BPD and recent suicidal/self-harm behavior. 6 months of DBT vs 6 months of SSRI with clinical management (SSRI/M)
- Significantly fewer suicide-related events (SREs) in DBT vs SSRI/M during the 6-month treatment phase. Significantly fewer suicide attempts in DBT arm
- Survival analysis: significantly lower risk of any SRE in DBT compared to SSRI/M
- Two-thirds of participants had comorbid major depressive disorder — DBT superiority held regardless of depression comorbidity
This is the study the field has been waiting for. Not DBT versus waitlist. Not DBT versus treatment-as-usual. DBT versus the most commonly prescribed pharmacological intervention for suicidal BPD patients — SSRIs with clinical management. Published in the American Journal of Psychiatry, it provides the first randomised head-to-head comparison. DBT wins.
The design that matters
Previous DBT trials compared it to waitlist, community treatment, or "expert" non-DBT therapy. The clinical question that prescribers actually face — should I refer for DBT or start an SSRI? — was unanswered. This trial answers it directly.
Eighty-four participants with BPD, multiple recent suicide attempts or self-injury episodes, randomised to either 6 months of full DBT (individual therapy, skills group, phone coaching, therapist consultation team) or 6 months of SSRI with structured clinical management. Two-thirds had comorbid MDD — these are the exact patients who might "reasonably" be started on an antidepressant instead of being referred to an intensive psychotherapy programme.
What the data shows
During the 6-month treatment phase, the DBT group had significantly fewer suicide-related events and fewer suicide attempts. Survival analysis confirmed a lower hazard of any SRE in DBT. The effect was not explained by depression improvement — DBT's advantage held in the comorbid MDD subgroup.
This is not a surprise to DBT-trained clinicians. But it matters enormously for systems. Every time a suicidal BPD patient is started on an SSRI instead of being referred for DBT, the evidence now says that decision carries measurably higher risk.
For your practice
If you prescribe for BPD patients: this trial does not say "stop SSRIs." It says "SSRIs alone are not sufficient for suicidal behavior in BPD, and DBT should be the primary intervention." If you are a therapist: this is your strongest evidence yet that DBT referral should precede, not follow, pharmacological intervention for suicidal BPD.
The first head-to-head RCT of DBT versus SSRIs for suicidal BPD shows DBT produces significantly fewer suicide attempts — the evidence prescribers needed to prioritise therapy referral over medication.
n=84 — modest sample. 6-month treatment phase — longer follow-up needed. Full DBT requires significant resources (therapist team, skills group) — not universally available.